These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

729 related items for PubMed ID: 22546554

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Gut microbiota, intestinal permeability, obesity-induced inflammation, and liver injury.
    Frazier TH, DiBaise JK, McClain CJ.
    JPEN J Parenter Enteral Nutr; 2011 Sep; 35(5 Suppl):14S-20S. PubMed ID: 21807932
    [Abstract] [Full Text] [Related]

  • 5. Nonalcoholic fatty liver disease: for better or worse, blame the gut microbiota?
    Li DY, Yang M, Edwards S, Ye SQ.
    JPEN J Parenter Enteral Nutr; 2013 Nov; 37(6):787-93. PubMed ID: 23538296
    [Abstract] [Full Text] [Related]

  • 6. Gut microbiota drives metabolic disease in immunologically altered mice.
    Chassaing B, Aitken JD, Gewirtz AT, Vijay-Kumar M.
    Adv Immunol; 2012 Nov; 116():93-112. PubMed ID: 23063074
    [Abstract] [Full Text] [Related]

  • 7. Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease.
    Paolella G, Mandato C, Pierri L, Poeta M, Di Stasi M, Vajro P.
    World J Gastroenterol; 2014 Nov 14; 20(42):15518-31. PubMed ID: 25400436
    [Abstract] [Full Text] [Related]

  • 8. Effects of the gut microbiota on obesity and glucose homeostasis.
    Greiner T, Bäckhed F.
    Trends Endocrinol Metab; 2011 Apr 14; 22(4):117-23. PubMed ID: 21353592
    [Abstract] [Full Text] [Related]

  • 9. Gut microbiota and non-alcoholic fatty liver disease: new insights.
    Aron-Wisnewsky J, Gaborit B, Dutour A, Clement K.
    Clin Microbiol Infect; 2013 Apr 14; 19(4):338-48. PubMed ID: 23452163
    [Abstract] [Full Text] [Related]

  • 10. Structural changes of gut microbiota in a rat non-alcoholic fatty liver disease model treated with a Chinese herbal formula.
    Yin X, Peng J, Zhao L, Yu Y, Zhang X, Liu P, Feng Q, Hu Y, Pang X.
    Syst Appl Microbiol; 2013 May 14; 36(3):188-96. PubMed ID: 23453736
    [Abstract] [Full Text] [Related]

  • 11. Gut-liver axis, nutrition, and non-alcoholic fatty liver disease.
    Kirpich IA, Marsano LS, McClain CJ.
    Clin Biochem; 2015 Sep 14; 48(13-14):923-30. PubMed ID: 26151226
    [Abstract] [Full Text] [Related]

  • 12. Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice.
    De Minicis S, Rychlicki C, Agostinelli L, Saccomanno S, Candelaresi C, Trozzi L, Mingarelli E, Facinelli B, Magi G, Palmieri C, Marzioni M, Benedetti A, Svegliati-Baroni G.
    Hepatology; 2014 May 14; 59(5):1738-49. PubMed ID: 23959503
    [Abstract] [Full Text] [Related]

  • 13. Gut-liver axis and fibrosis in nonalcoholic fatty liver disease: an input for novel therapies.
    Frasinariu OE, Ceccarelli S, Alisi A, Moraru E, Nobili V.
    Dig Liver Dis; 2013 Jul 14; 45(7):543-51. PubMed ID: 23280158
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Prebiotic effects: metabolic and health benefits.
    Roberfroid M, Gibson GR, Hoyles L, McCartney AL, Rastall R, Rowland I, Wolvers D, Watzl B, Szajewska H, Stahl B, Guarner F, Respondek F, Whelan K, Coxam V, Davicco MJ, Léotoing L, Wittrant Y, Delzenne NM, Cani PD, Neyrinck AM, Meheust A.
    Br J Nutr; 2010 Aug 14; 104 Suppl 2():S1-63. PubMed ID: 20920376
    [Abstract] [Full Text] [Related]

  • 16. Gut microbiota and its pathophysiology in disease paradigms.
    Festi D, Schiumerini R, Birtolo C, Marzi L, Montrone L, Scaioli E, Di Biase AR, Colecchia A.
    Dig Dis; 2011 Aug 14; 29(6):518-24. PubMed ID: 22179206
    [Abstract] [Full Text] [Related]

  • 17. Host-gut microbiota metabolic interactions.
    Nicholson JK, Holmes E, Kinross J, Burcelin R, Gibson G, Jia W, Pettersson S.
    Science; 2012 Jun 08; 336(6086):1262-7. PubMed ID: 22674330
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Gut-liver axis and microbiota in NAFLD: insight pathophysiology for novel therapeutic target.
    Miele L, Marrone G, Lauritano C, Cefalo C, Gasbarrini A, Day C, Grieco A.
    Curr Pharm Des; 2013 Jun 08; 19(29):5314-24. PubMed ID: 23432669
    [Abstract] [Full Text] [Related]

  • 20. The gut microbial metabolome: modulation of cancer risk in obese individuals.
    Russell WR, Duncan SH, Flint HJ.
    Proc Nutr Soc; 2013 Feb 08; 72(1):178-88. PubMed ID: 23174203
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.